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AbstrACt 
Purpose The Hortega Study is a prospective study, 
which investigates novel determinants of selected 
chronic conditions with an emphasis on cardiovascular 
health in a representative sample of a general population 
from Spain.
Participants In 1997, a mailed survey was sent to a 
random selection of public health system beneficiaries 
assigned to the University Hospital Rio Hortega’s 
catchment area in Valladolid (Spain) (n=11 423, phase 
I), followed by a pilot examination in 1999–2000 of 
495 phase I participants (phase II). In 2001–2003, the 
examination of 1502 individuals constituted the Hortega 
Study baseline examination visit (phase III, mean age 48.7 
years, 49% men, 17% with obesity, 27% current smokers). 
Follow-up of phase III participants (also termed Hortega 
Follow-up Study) was obtained as of 30 November 2015 
through review of health records (9.5% of participants 
without follow-up information).
Findings to date The Hortega Study integrates baseline 
information of traditional and non-traditional factors 
(metabolomic including lipidomic and oxidative stress 
metabolites, genetic variants and environmental factors, 
such as metals), with 14 years of follow-up for the 
assessment of mortality and incidence of chronic diseases. 
Preliminary analysis of time to event data shows that 
well-known cardiovascular risk factors are associated with 
cardiovascular incidence rates, which add robustness to 
our cohort.
Future plans In 2020, we will review updated health 
and mortality records of this ongoing cohort for a 5-year 
follow-up extension. We will also re-examine elder 
survivors to evaluate specific aspects of ageing and 
conduct geolocation to study additional environmental 
exposures. Stored biological specimens are available for 
analysis of new biomarkers. The Hortega Study will, thus, 
enable the identification of novel factors based on time to 
event data, potentially contributing to the prevention and 
control of chronic diseases in ageing populations.
IntroduCtIon
Traditional cardiovascular risk factors do 
not completely explain the development 
strengths and limitations of this study
 ► The main strengths of the Hortega Study (n=1502) 
include the complex sampling design, the 14-year 
follow-up for the assessment of incident chron-
ic disease, the extended array of readily available 
baseline measurements of traditional and non-tra-
ditional risk factors, and the associated biological 
specimens that allow ancillary studies.
 ► About 54 of baseline (phase III) participants moved 
out of the catchment area during the follow-up and 
were losses to follow-up because of no access to 
their health records; they showed somewhat young-
er and healthier baseline profile compared with the 
overall, which may bias the association of risk fac-
tors with health endpoints against the null.
 ► About 40 of baseline participants lacked follow-up 
information on the health records and their ad-
ministrative profile was inactive (eg, people using 
private insurances) and were considered losses to 
follow-up; they showed a worse baseline risk profile 
compared with the overall, which may bias the asso-
ciation of risk factors with health endpoints towards 
the null.
 ► About 42 of baseline participants lacked follow-up 
information on the health records and were consid-
ered as administrative censures because they did 
not use the public health system, but they had an 
active administrative profile and were reasonably 
healthier at baseline compared with the overall, al-
though we cannot discard that they may have pro-
spectively developed undiagnosed risk factors.
 ► While the statistical power is only moderate, we 
empirically detected multi-adjusted HRs for cardio-
vascular incidence associated with most traditional 
risk factors in sex strata and the power substantially 
increases for the analysis of continuous endpoints.
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of cardiovascular disease (CVD).1 2 Given the elevated 
burden of vascular diseases in increasingly growing 
ageing populations, identifying novel factors and mech-
anisms for cardiovascular risk is urgently needed. 
Mounting evidence point to a number of non-traditional 
factors that may influence cardiovascular risk including 
oxidative stress and inflammation,3–5 metabolic,6 genetic7 
and environmental factors such as metals.8 9 However, 
population-based studies which evaluate the potential 
cardiometabolic effects of these factors in representative 
samples of the general population are scarce.
The Hortega Study is a population-based survey among 
adults residing in the catchment area of the University 
Hospital Rio Hortega (UHRH) (Health Department of 
Eastern Valladolid, Spain), which aims to investigate the 
cross-sectional and prospective association of genetic, 
metabolomic (including lipidomics and oxidative stress 
metabolites) and environmental risk factors with selected 
chronic conditions, with a special interest on CVD. The 
follow-up of 1502 Hortega Study participants (baseline 
examination visit and collection of biological specimens 
in 2001–2003), added information on mortality and inci-




The Hortega Study was obtained through a multi-stage 
complex sampling, which allows to make inferences that 
are representative of the target general population. In 
Spain, tertiary hospitals, such as UHRH, have specific 
geographic areas for patient referral and integrate the 
network of primary care centres in each area. UHRH is 
a public hospital of 600 beds with a healthcare coverage 
close to the 95% of the population living in the area. 
The Hortega Study phase I started in 1997 by randomly 
selecting ~20% of the general population 14–85 years in 
the list of beneficiaries of the public health system assigned 
to the UHRH catchment area (reference population of 
179 505 subjects). Accordingly, during 1997–1998 vali-
dated questionnaires were sent by mail to 34 742 subjects 
with a response rate of ~33% (n=11 423). Subsequently, 
in 1998, a phone interview was conducted to identify 
whether characteristics of 500 randomly selected non-re-
sponders were similar to responders. The prevalence of 
self-reported hypertension, diabetes and dyslipidaemia 
was, respectively, 12.5%, 5.1% and 17.2% for respondents 
and 14.9%, 5.7% and 12.6% for non-respondents (online 
supplemental material and table 1). In phase II, we 
randomly selected 1502 subjects from six strata defined 
by age and sex among the 11 423 phase I participants who 
responded to the mail survey, and a second extended 
questionnaire was mailed to them. About 48.2% of the 
selected population responded to the questionnaires 
(724 participants). The distribution of participant char-
acteristics comparing respondents and non-respondents 
was similar (online supplemental material and table 
1). We then conducted a pilot examination among 495 
respondents, who were appointed for an examination 
visit in the medical office.
In phase III (2001–2003), the 1502 participants initially 
selected in phase II were invited for the Hortega Study 
baseline examination visit, including the 495 phase II 
pilot examination visit participants. Among those, 62% 
accepted and 2% passed away in the period between 
phases II and III. For a given age and sex strata, we 
randomly replaced non-respondent participants with 
other phase I participants who had a similar CVD risk 
factor profile according to a prime number classification 
system (see online supplemental material, methods and 
table 2). As a result, the age, sex and cardiovascular risk 
factors distributions in the final Hortega phase III sample 
(n=1502), closely reflect those of the target population. 
Biological samples including urine, plasma and buffy coat 
for DNA extraction were collected and stored at −80°C 
from all Hortega phase III participants. In 2015, the 
Hortega Follow-up Study was launched as the follow-up of 
phase III participants, by actively searching in the health 
records, which included records from hospital admis-
sions, medical office visits, pharmacy information and 
laboratory tests, both from Primary and Specialised Care. 
Figure 1 illustrates the study design and timeline.
data collection
Table 1 summarises the timing and specific details of the 
different data collected in the Hortega Study. In brief, 
data collected from the mailed questionnaires in phase I 
included information such as age, sex, address, education 
level, weight, height, lifestyle habits (tobacco smoking, 
alcohol drinking), but also other factors associated with 
cardiometabolic risk, such as medical history of hyper-
tension, diabetes, dyslipidaemia, CVD and related treat-
ments. The extended questionnaires mailed in phase II 
to 1500 individuals collected information on cardiovas-
cular risk factors, socio-demographic characteristics (civil 
status, number of family members, any dependency), 
healthcare use (medication, visits to the family doctor, 
emergency room, specialists), physical exercise, quality 
of life (SF36), nutrition (semi-quantitative diet and two 
24hour recall). The phase II pilot examination provided 
the opportunity to validate the mailing interview. In addi-
tion, anthropometric data and blood pressure (BP) values 
were measured, and urine and blood samples were 
collected. In phase III, the examination visit of phase 
II participants (including re-examination of those who 
participated in the pilot examination), integrated infor-
mation from an extended array of determinations for the 
assessment of traditional and non-traditional CVD risk 
factors and biological sample collection including urine, 
plasma  and buffy coat, which together with the follow-up 
of phase III participants for the assessment of mortality 
and incident chronic diseases, constitute the basis for the 
Hortega Follow-up Study. We provide below specific infor-
mation of phase III data collection including endpoints 
assessment during follow-up.
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Cardiovascular risk factors
We had an a priori interest on the prevalence of cardiomet-
abolic factors. Body mass index was calculated using 
measured height and weight. BP was measured using an 
OMRON Hem-711C automated device (OMRON Health-
care, USA) following the recommendations of the British 
Hypertension Society and the Association for the Advance-
ment of Medical Instrumentation. Accordingly, systolic 
Figure 1 Hortega Study design and timeline. The Hortega Study was initiated in 1997 as a mailed survey on a random 
selection of public health system beneficiaries assigned to the University Hospital Rio Hortega‘s catchment area in Valladolid 
(Spain) (n=11 423, phase I), followed by a pilot examination in 1999–2000 of 495 phase I participants (phase II). In 2001–2003, 
the examination of 1502 individuals (including the re-examination of pilot examination participants) constituted the Hortega 
Study baseline examination visit (phase III). Follow-up of phase III participants (also termed Hortega Follow-up Study) was 
obtained as of 30 November 2015 through review of health records. About 9.5% of participants did not have follow-up 
information (among them 101 participants were considered losses to follow-up and 42 were considered administrative censures 
because they did not use the public health system, but they had an active administrative profile and were reasonably healthier 
at baseline compared with the overall).
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BP (SBP) and diastolic BP (DBP) were the average of two 
readings measured at 5 min intervals. Hypertension was 
defined as a mean SBP greater than 140 mm Hg, a mean 
DBP greater than 90 mm Hg, a recorded physician diag-
nosis or medication use. Urine cotinine was measured by 
enzyme-linked immunosorbent assay (Kit ‘Análisis DRI 
Cotinina’, Ref. 0395 Microgenics laboratories). Blood 
samples were obtained after an average of 3 hours since 
the last intake of food (range 0–17). Non-fasting glucose 
was measured in the whole study population by the 
glucose oxidase method with a Hitachi 704 autoanalyzer 
(Roche Boehringer, Germany). In a second step, fasting 
glucose determinations were obtained only in partic-
ipants with non-fasting glucose levels equal or higher 
than 140 mg/dL. Glycosylated haemoglobin (HbA1c) 
levels were measured from capilar blood samples with 
a DCA 2000 HbA1c analyzer (Bayer Diagnostics, USA). 
Subjects were considered as having diabetes if they had 
a record of type 2 diabetes diagnosis or a record of use 
of diabetes medications in the clinical history, if fasting 
plasma glucose was >126 mg/dL, or if HbA1c was ≥6.5%. 
Non-fasting total, high-density lipoprotein cholesterol 
and triglicerides concentrations were determined with an 
Hitachi 917 autoanalyzer (Roche Boheringer). Low-den-
sity lipoprotein (LDL)-cholesterol levels were estimated 
with the Friedewald formula. Dyslipidaemia was defined 
as a total cholesterol >200 mg/dL or medication use. 
Urine and serum creatinine were measured by the modi-
fied kinetic Jaffé method by isotope dilution mass spec-
trometry on a Hitachi 917 analyzer (Roche Boheringer). 
The glomerular filtration rate was estimated based on 
serum creatinine determinations (eGFR) by the CKD-EPI 
abbreviated.10 Urine albumin was measured by auto-
mated nephelometric immunochemistry (Behring, 
Germany). The ratio of urinary albumin to urinary creat-
inine (ACR) was reported in milligrams per gram. We 
Table 1 Data items collected in the Hortega follow-up study
Phase Measurements
I (1997) Questionnaire design and validation, and initial mailing to the ~20% of the beneficiaries of the public 
health system assigned to the UHRH (n=34 742).
II (1999–2000) Random selection of 1502 individuals according to age and sex strata. Extended questionnaire by 
mail and examination and blood samples collection of 495 selected individuals (pilot examination).
III (2001–2003) Examination of 1502 participants (including re-examination of phase II participants from the pilot 
examination) and biological sample collection including urine, plasma and buffy coat. Measurements:
 ► Urine: sodium, potassium, calcium, phosphorus, creatinine, standard (immunogenic) albumin, 
high-performance liquid chromatography-based (non-immunogenic) albumin, copper, 
zinc, selenium, lead, cadmium, arsenic, cobalt, chromium, cotinine, GSSG, GSH, 8-oxo-7, 
8-dihydroguanine, malondialdehyde, norepinephrine, epinephrine, dopamine, nitrates and nitrites.
 ► Non-fasting standard plasma biochemistry (information on average hours since the last intake 
of food was also collected): glucose, total cholesterol,    high-density lipoprotein cholesterol, 
low-density lipoprotein cholesterol, triglycerides, creatinine, uric acid, sodium, copper, zinc, 
selenium, aluminium, arsenic, high-sensitivity C reactive protein, thyroid hormones, anti-thyroid 
antibodies and metabolomics profile.
 ► Genetic single nucleotide polymorphisms related with cardiovascular risk including the renin–
angiotensin–aldosterone system, diabetes, dyslipidaemia and oxidative stress and metal 
transporters. Targeted next generation sequencing of candidate regions.
 ► Clinical parameters and medical history: age, gender, weight, height, body mass index, place 
of residence, waist circumference, hip, thigh and upper arm, social class, education level, 
profession, marital status, medical services attendance (primary care, emergency room, outpatient 
clinic, time off work, prescription drug use), bone densitometry (Lunar Pixi), quality of life scales 
(Euroqol EQ-5D, short-form 36, Profile of Life quality in the Chronically Ill (PLC-PECVEC), Older 
Americans Resources and Services in subjects older than 65 years), hypertension status, office 
blood pressure (BP) measurements (two measurements), 24 hours ambulatory monitoring (in 
500 subjects with a history of hypertension, newly diagnosed hypertension or in secondary 
prevention of cardiovascular disease), estimation of physical activity in metabolic equivalents 
(METS) (during walking and other types of physical activities), Epworth Sleepiness Scale, smoking 
status (pack-years, time since smoking cessation, age at smoking onset, daily tobacco exposure, 
Fagerstrom Test for Nicotine Dependence), alcohol consumption and types of alcohol, dietary 
intake estimation (24 hours food diaries, semi-quantitative survey, nutrition knowledge survey, 
conversion to nutrients, vitamins and trace elements), Edinburgh Claudication Questionnaire for 
detecting peripheral arterial disease.
Follow-up study (2015) 13-year follow-up of phase III participants for total mortality and incidence of chronic disease, 
especially cardiovascular, but also cancer, bone fractures, diabetes, hypertension, dyslipidaemia and 
chronic kidney disease.
GSH, reduced glutathione; GSSG, oxidised glutathione; UHRH, University Hospital Rio Hortega.
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defined abnormal albuminuria as an ACR greater than 
or equal to 30 mg/g. Chronic kidney disease was defined 
as the presence of a glomerular filtration rate lower than 
60 mL/min/1.73 m2 or abnormal albuminuria.
Biomarkers of exposure to trace elements
Total plasma metal and metalloid levels (including 
arsenic, zinc, selenium and copper) were determined by 
atomic absorption spectrometry with graphite furnace on 
a Varian AAS 240 Zeeman (Varian, USA) at Cerba Inter-
national Laboratories. Total urine metals and metalloids 
(cadmium, cobalt, copper, molybdenum, zinc, antimony, 
barium, cadmium, chromium, vanadium, arsenic) and 
arsenic species concentrations were measured by induc-
tively coupled-plasma mass spectrometry (ICPMS) on 
an Agilent 7500CEx ICPMS equipped with an octapole 
collision cell (Agilent Technologies, Japan) and by an 
ICPMS Thermo XSeries2 (Thermo Scientific, Germany) 
equipped with an octapole reaction cell, coupled to an 
anion exchange liquid chromatography (IEC-HPLC) 
system on a Agilent 1100 (Agilent, USA), respectively, 
following a standardised protocol in the Laboratory of 
Environmental Chemistry and Bioanalysis of Huelva 
University (Spain). The determination of urine arsenic 
species, including arsenite, arsenate, methylarsonate, 
dimethylarsinate and arsenobetaine occurred only in a 
random subsample of 295 individuals, which allows the 
implementation of multiple imputation strategies for 
values missing completely at random in the remaining 
cohort as done by our group in previous studies.11–13
Oxidative stress biomarkers
We measured commonly used biomarkers of oxida-
tive stress including the oxidised (GSSG) to reduced 
(GSH) glutathione ratio (GSSG/GSH), malondialde-
hyde (MDA) and damaged base 8-oxo-2'-deoxyguano-
sine (8-oxo-dG). GSSG/GSH, MDA and 8-oxo-dG were 
measured in urine. GSSG and GSH were analysed by 
high-performance liquid chromatography (HPLC). MDA 
was analysed by HPLC and spectrophotometric quan-
tification of MDA-thiobarbituric acid at 532 nm. The 
amount of 8-oxo-dG in urine was measured by HPLC with 
electrochemical detection (HPLC-EC). The equipment 
for oxidative stress biomarkers determinations included 
a Waters 600 controller including a Waters 515 HPLC 
pump and two Waters 2487 dual absorbance detectors 
(Waters, USA).
NMR spectroscopy
We determined the metabolomics spectrum using nuclear 
magnetic resonance (NMR). Eighty-two microliters of 
D2O were added to 418 µL of blood plasma and placed 
in a 5-mm NMR tube. About 1 hour NMR spectra were 
recorded using a Bruker Avance DRX 600 spectrometer 
(Bruker GmbH, Germany). Nominal temperature of the 
sample was kept at 37°C. A single-pulse pre-saturation 
experiment was acquired in all samples. The spectra were 
referenced using the doublet of alanine at 1478 ppm. 
The chemical shift region, including resonances between 
0.50 and 4.70 parts per million (ppm) of spectrometer 
frequency, was investigated. The spectra were binned 
into 0.01 ppm buckets and normalised to total aliphatic 
spectral area to eliminate differences in metabolite total 
concentration. Signals belonging to selected metabolites 
were quantified using semi-automated in-house MATLAB 
V.6.5 integration and peak-fitting routines. Reproduc-
ibility of NMR spectroscopy was tested by superposition of 
normalised spectra of blood serum. Chenomx NMR Suite 
V.4.5 software and two-dimensional (2D) NMR methods 
including homonuclear correlation spectroscopy and 
heteronuclear single quantum correlation spectroscopy 
were used to identify and subsequently confirm the assess-
ment of metabolites.
In parallel, we also assessed lipid particles profiles using 
the LIPOSCALE methods for analysis of NMR spectra. 
About 500 µL of blood plasma samples were shipped on 
dry ice to Biosfer Teslab (Reus, Spain) for lipoprotein 
analysis by NMR on a Bruker Avance III 600 spectrometer 
(Bruker GmbH) operated at proton frequency of 600.20 
MHz. Particle concentration and the diffusion coeffi-
cients were obtained from the measured amplitudes and 
attenuation of their spectroscopically distinct lipid methyl 
group NMR signals using the 2D diffusion-ordered 1 hour 
NMR spectroscopy pulse. The methyl signal was surface 
fitted with three Lorentzian functions associated with 
each lipoprotein subtypes: large, medium and small of 
the VLDL, LDL and HDL. The area of each Lorentzian 
function was related to the lipid concentration of each 
lipoprotein subtype, and the size of each subtype was 
calculated from their diffusion coefficient. The particle 
numbers of each lipoprotein subtype were calculated 
by dividing the lipid volume by the particle volume of a 
given class. The lipid volumes were determined by using 
common conversion factors to convert concentration 
units into volume units.
Candidate single nucleotide polymorphisms
We isolated DNA from peripheral blood cells using 
Chemagic System (Chemagen, USA), and quantified it 
with PicoGreen dsDNA Quantification Reagent (Invi-
trogen, USA). DNA was diluted to a final concentra-
tion of 100 ng/µL. We used bibliography searches and 
the SYSNPS programme, based on public data sources 
including Ensembl and HapMap (GRCh36), to identify 
1251 single nucleotide polymorphisms (SNPs) from 416 
candidate genes implicated cardiometabolic pathways, 
such as inflammation, redox homeostasis, response to 
insulin or others (see complete list of genes and SNPs in 
online supplemental material and table 3). We included 
genes with available preliminary data in support of their 
association with health outcomes in humans, including 
genes reported in the literature. The SNPs were geno-
typed using an oligo-ligation-assay (SNPlex, Applied 
Biosystems, USA) following the manufacturer’s guide-
lines. Moreover, we have available funding for next 
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generation sequencing of additional ~200 candidate 
regions associated to cardiometabolic risk.
Linkage to morbidity, mortality and other routine data sources
In the Hortega Study, the in-person interview and exam-
ination visit was only conducted at baseline (phase III). 
Information for the 14-year follow-up was adjudicated by 
reviews of clinical records. Patient data was saved from 
various occasions and locations where they had received 
care, such as in the primary care physician’s office, as well 
as other physician specialists, nurses’ offices, pharmacies, 
hospitals and emergency departments. We thus extracted 
patient medications, vital status, medical history and 
laboratory data, among others, which was linked to the 
diagnostics and mortality reports generated during hospi-
talisations. Table 2 shows the distribution of participant 
characteristics by subgroups with different reasons for not 
having follow-up information in the health records.
The primary outcome of this study was cardiovascular 
incidence, including both fatal and non-fatal events. 
Detailed definitions of specific cardiovascular events 
follow the guidelines published by the 2014 American 
College of Cardiology and American Heart Association 
Task Force of Clinical Data Standards Committee.14 
Participant were considered as having incident diabetes, 
hypertension, dyslipidaemia or chronic kidney disease, if 
they were not prevalent cases of such conditions at the 
time of the baseline examination and they fulfilled the 
corresponding standard definitions during the follow-up 
based on the health records. Time to event was calculated 
as the difference between the date of the baseline exam-
ination and the date of the event, the date of death or 
30 November 2015 (administrative censoring), whichever 
occurred first. Records from all phase-III Hortega partic-
ipants were reviewed by a committee composed of two 
physician reviewers who assigned incident events with no 
a priori knowledge of who may or may have not devel-
oped CVD events. We additionally collected information 
on incidence of other chronic diseases. For instance, 
incident cancer cases and associated time to event vari-
ables were defined based on the date of the first positive 
pathology report in the health record. Incident fractures 
(mainly, hip, humerus, vertebral and Colles fractures) and 
associated time to event were defined based on the date 
of the first pathological imaging technique (including 
X-ray, CT scan or NMR).
Patient and public involvement
Patients were not involved in the Hortega Follow-up 
Study as the follow-up data of Hortega Phase III partic-
ipants was obtained by review of electronic health 
records.
Table 2 Age-adjusted participants’ baseline characteristics overall and in subgroups lost to follow-up
Overall
(n=1502)
Patients who did not 
use the public health 







Patients who did not use 
the public health system 
with inactive administrative 
profile
(n=40)
Age, years; mean 48.7 36.6 41.2 47.9
Male; % 49.0 62.2 52.7 54.0
Obesity; %* 16.7 6.3 11.4 25.2
Former smoking; %† 28.6 38.2 17.4 38.3
Current smoking; %† 27.0 31.3 22.6 34.0
Diabetes; % 6.3 0.0 3.3 3.0
Glucose lowering medication; % 3.1 0.0 2.2 3.0
Hypertension; % 36.1 7.1 24.9 39.7
Antihypertensive medication; % 14.7 2.2 7.4 12.9
eGFR<60 mL/min/1.72 m2; % 6.7 0.0 2.1 7.0
Dyslipidaemia; %‡ 52.7 40.1 45.4 58.6
Lipid lowering medication; %‡ 6.0 0.0 5.3 12.4
Former alcohol intake, %§ 9.0 14.6 13.2 3.2
Current alcohol intake, %§ 53.1 61.1 56.1 47.1
Prevalent CVD, % 6.3 0.0 0.0 0.0
*58 participants missing obesity.
†20 participants missing smoking.
‡Five participants missing lipids.
§Eight participants missing alcohol.
CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate.
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Future plans
Starting in 2020, we will review updated health records to 
extend the follow-up for additional 5 years. We will also be 
periodically obtaining updated mortality information of 
the Hortega Study participants from the Spanish National 
Institute for Statistics. Moreover, the geocoding of the 
participants’ home addresses (which will be conducted in 
collaboration with the Department of Chronic Diseases 
Epidemiology at the National Center of Epidemiology, 
Instituto de Salud Carlos III, Madrid) will allow to eval-
uate additional environmental factors that may influ-
ence health. In addition, there is a plan to re-contact 
and re-examine survivors older than 65-year-old (n=600) 
with the objective to evaluate specific aspects of ageing. 
Another prospective goal is to enrich already-collected 
data through the addition of ‘-omics’ data (ie, DNA meth-
ylation or exome sequencing) as well as new phenotypic 
data.
FIndIngs to dAte
The phase III Hortega Examination visit has generated 
numerous cross-sectional studies of traditional (including 
diabetes,15 hypertension16 and dyslipidaemia17) and 
non-traditional (genetic,15 17–20 metabolomics21 22 and envi-
ronmental23–27) cardiovascular risk factors. The follow-up 
data from the Hortega Study will allow to conduct time 
to event survival analysis and other prospective studies 
which will provide novel evidence on the potential role 
of genetic, environmental and metabolomic factors in 




Total mortality Combined CVD
n (%)
Total mortality Combined CVD
Cases Rate Cases Rate Cases Rate Cases Rate
Overall 599 (100) 121 100.4 82 84.4 630 (100) 75 49.5 65 52.9
Age group (years)
  <50 300 (58.5) 6 14.8 8 20.9 329 (57.2) 2 4.6 5 12.2
  50–65 112 (22.4) 8 54.3 10 70.2 96 (17.4) 4 31.1 7 55.6
  65–75 87 (10.2) 33 283.1 29 315.0 96 (13.3) 20 134.9 21 166.1
  ≥75 100 (8.9) 74 835.3 35 476.6 109 (12.1) 49 418.5 32 305.8
BMI
  <30 502 (84.2) 97 98.3 69 89.7 517 (83.2) 50 48.2 42 49.4
  ≥30 97 (15.8) 24 113.4 13 66.0 113 (16.4) 25 54.4 23 62.8
Smoking
  Never 196 (33.0) 29 66.8 20 56.6 378 (56.4) 68 49.5 55 42.8
  Former 241 (36.7) 79 118.8 49 75.3 111 (19.1) 4 36.9 5 46.4
  Current 162 (30.3) 13 109.9 13 106.4 141 (24.5) 3 65.2 5 96.5
Hypertension
  No 352 (64.8) 28 79.4 23 77.5 384 (64.8) 16 49.8 10 31.7
  Yes 247 (35.2) 93 132.5 59 118.0 246 (35.2) 59 59.2 55 83.4
Diabetes mellitus
  No 545 (92.7) 91 96.5 61 77.6 598 (95.8) 61 47.4 54 51.1
  Yes 54 (7.3) 30 157.1 21 179.9 32 (4.2) 14 109.3 11 140.6
Dyslipidaemia
  No 395 (66.4) 83 106.9 46 71.9 402 (65.3) 38 51.0 28 48.8
  Yes 204 (33.6) 38 87.0 36 111.0 228 (34.7) 37 47.0 37 59.8
Combined CVD definition included fatal and non-fatal CHD, stroke, heart failure and peripheral arterial disease.
*We excluded 81 participants missing baseline obesity, smoking or lipid determinations, 89 participants lost to follow-up, 7 participants who 
died but the date of death was unknown and 96 participants with prevalent coronary heart disease, stroke, heart failure or peripheral arterial 
disease at baseline, leaving 1229 individuals for the prospective analysis. Summary age-adjusted rates for all-cause mortality and combined 
cardiovascular incidence were estimated from Poisson regression models for individual mortality and cardiovascular incidence time-to-event 
data (endpoint status at the end of follow-up as dichotomous outcome and log-transformed individual follow-up time as offset). All analyses 
were weighted to the underlying population. Average and absolute amount of follow-up was, respectively, 12.5 and 15 402.8 person-year for 
mortality and 12.0 and 14 784.4 person-year for combined CVD.
BMI, body mass index; CVD, cardiovascular disease.
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the pathogenesis of chronic disease, mainly cardiovas-
cular, but also other such as cancer, and bone disease. So 
far, we have identified 277 deaths and several incident 
endpoints, such as all-cause CVD (n=179), all-cancer 
(n=140) and fractures (n=77). Table 3 shows age-ad-
justed total mortality and cardiovascular incidence rates 
by subgroups defined by traditional cardiovascular risk 
factor, which are consistent with published data from 
other cardiovascular cohorts and add robustness to our 
cohort.
strengths and limitations
The main strength of the Hortega Study is that it is a 
representative sample of a general population from 
Spain, with associated biological specimens and follow-up 
for assessment of incident chronic diseases, with a special 
interest in traditional and non-traditional factors associ-
ated with cardiometabolic risk, and an extended array of 
readily available measurements including cardiovascular 
risk factors and treatments, dietary and physical activity 
habits, anthropometric measures, standard plasma 
biochemistry profile, urine oxidative stress biomarkers, 
genetic polymorphisms, quality of life and lifestyle-related 
questionnaires, biomarkers of environmental exposures, 
such as urinary metals and metabolic compounds from 
metabolomics platforms. Men and women and a wide age 
range are represented, including participants from rural 
and urban areas. Another strength is provided by the 
consent form, which was approved by the corresponding 
Ethics committees and allow ancillary studies. Thus, 
future studies making use of the Hortega Study data and 
samples are possible.
The Hortega Follow-up Study is not exempt of limita-
tions. In phase III, only 62% of individuals who answered 
the questionnaires in initial stages of the sampling 
process, agreed to participate in the physical examina-
tion. However, we implemented a complex stratified 
system based on prime numbers to randomly replace 
non-participating individuals by other who did belong to 
the same poli-strata defined by cardiovascular risk profile, 
sex and age (see online supplemental maerial, methods 
and table 1). Consequently, the distribution of cardio-
vascular risk factors in the Hortega Study baseline exam-
ination visit (phase III) is the same as in the preliminary 
random selection of participants. However, during the 
follow-up period 7 participants died with unknown death 
date, 54 participants were assigned to another catch-
ment area and 82 did not use the public health system 
(among them 42 with and 40 without, active administra-
tive profile in file). Participants with an inactive adminis-
trative profile show a worse cardiovascular risk profile at 
baseline compared with the overall (table 2) and could 
have been out-of-catchment area deaths, people that 
changed address without having communicated it to the 
public health system or people using private insurances, 
and were considered loses to follow-up, which could have 
biased estimated relative risks towards the null. Partic-
ipants lost to follow-up due to a confirmed change of 
catchment area show a somewhat healthier cardiovas-
cular profile compared with the overall, which could bias 
the estimated relative risks against the null. Participants 
with active administrative profile in file but who did not 
contact the health system showed a markedly healthier 
cardiovascular profile at baseline, and it is likely that they 
did not undergo any hospitalisation. Consequently, we 
considered individuals with active administrative profile 
as reasonably ‘healthy’ and censored them at the end of 
the follow-up. We cannot discard, however, that some of 
these participants may have developed cardiovascular 
risk factors during the follow-up that have remained 
undiagnosed.
Other weaknesses include the lack of fasting plasma 
glucose determinations in the whole study population. 
Only individuals with suggestive evidence of altered 
fasting glucose levels underwent a second measurement 
in fasting conditions. This strategy allows for analysis of 
diabetes status but not for associations with glycaemia 
Table 4 HR (95% CI) for combined CVD incidence by traditional risk factors in CVD-free study participants (N=1229*).
Overall Men Women
Current smoker 1.55 (1.09 to 2.23) 1.29 (0.82 to 2.03) 2.25 (0.96 to 5.30)
Obesity 0.95 (0.77 to 1.17) 0.71 (0.48 to 1.05) 1.17 (0.84 to 1.63)
Hypertension 1.83 (1.40 to 2.40) 1.61 (1.17 to 2.23) 2.30 (1.22 to 4.33)
Diabetes 2.09 (1.55 to 2.81) 2.39 (1.44 to 3.96) 1.67 (0.81 to 3.42)
Dyslipidaemia 1.35 (1.12 to 1.63) 1.17 (0.87 to 1.57) 1.60 (1.09 to 2.35)
Combined CVD definition included fatal and non-fatal CHD, stroke, heart failure and peripheral arterial disease. aWe excluded 81 participants 
missing baseline obesity, smoking or lipid determinations, 89 participants lost to follow-up, 7 participants who died but the date of death was 
unknown and 96 participants with prevalent coronary heart disease, stroke, heart failure or peripheral arterial disease at baseline, leaving 1229 
individuals for the prospective analysis. Rate ratios for cardiovascular incidence associated with the presence of traditional cardiovascular 
risk factors were estimated from Poisson regression models of individual time-to-event data adjusting for age at follow-up, sex and traditional 
cardiovascular risk factors including smoking status (never, former, current), obesity (no, yes), dyslipidaemia (total cholesterol ≥200 mg/dL 
or lipid lowering medication), diabetes (no, yes), hypertension (no, yes), low-estimated glomerular filtration rate (no, yes), anti-hypertensive 
medication (no, yes), glucose lowering medication (no, yes) and lipid lowering medication (no, yes). All analyses were weighted to the 
underlying population.
CVD, cardiovascular disease. 
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as a continuous measure. An additional limitation is the 
moderate sample size. However, we have enough power 
to detect multi-adjusted HRs for cardiovascular incidence 
associated with most traditional risk factors in men and 
women (table 4). Table 4 empirically shows that we have 
enough power to detect a minimum of 60% change in 
cardiovascular risk associated with dichotomous variables 
in sex-specific analyses, when the number of cases among 
exposed is as low as 37 (eg, the association of dyslipaemia 
and combined CVD in women shown in tables 3 and 4). 
For analysis using continuous explanatory variables the 
power increases substantially.
Finally, the data are not publicly available as the steering 
committee and the participants have not approved unre-
stricted data sharing at the time of approval of the study 
by the corresponding ethics committee and unrestricted 
data sharing was not included in the consent form. There 
are however opportunities for collaboration and for ancil-
lary studies proposals as data are available on reasonable 
request (see the Data availability statement section).
CollAborAtIons
The available biological specimens (plasma, buffy coat, 
DNA) will add value to our cohort as potentially novel 
biomarkers of disease are identified and measured 
through prospective collaborations. The Hortega Study, 
a cohort from a south European population with elevated 
prevalence of traditional cardiovascular risk factor but 
low burden of disease, thus, offers substantial opportuni-
ties for collaborative proposals aiming to the identifica-
tion of novel biological mechanisms for disease and risk 
factors, which in turn could contribute to the prevention 
and control of chronic diseases in ageing populations.
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